Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer Diagnoses and Deaths in Hungary, 2011-2023: Nationwide Trends Before, During, and After the COVID-19 Pandemic.

Cancers·2026
Same author

Real-world evidence for the efficacy and tolerability of an isobutylamido-thiazolyl-resorcinol (Thiamidol)-containing skincare regimen on facial hyperpigmentation and overall skin appearance: A multi-centre study in 11 European countries.

International journal of cosmetic science·2026
Same author

Comparative performance of EQ-5D-5L bolt-ons in China and the Netherlands: results from the EQ-DAPHNIE project.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2026
Same author

Sulforaphane as a Photoprotective Agent Against UV-Induced Skin Damage and Carcinogenesis: A Scoping Review.

Journal of personalized medicine·2026
Same author

Upregulated GLUT1 expression correlates with type I interferon activity and disease severity in cutaneous lupus erythematosus.

Journal of translational autoimmunity·2026
Same author

Psychometric properties of four FACE-Q Aesthetics scales in patients planning and undergoing minimally invasive facial cosmetic procedures.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2026

Related Experiment Video

Updated: Sep 3, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K

Anti-PD-1 Monotherapy in Advanced Melanoma-Real-World Data from a 77-Month-Long Retrospective Observational Study.

Daniella Kuzmanovszki1, Norbert Kiss1, Béla Tóth1

  • 1Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, 41 Mária u., H-1085 Budapest, Hungary.

Biomedicines
|July 27, 2022
PubMed
Summary

Immune checkpoint inhibitors (ICIs) improve outcomes in advanced melanoma. Experiencing more than one immune-related adverse event (irAE) correlated with better survival, suggesting irAEs may predict treatment response.

Keywords:
advanced melanomaadverse eventanti-PD-1 monotherapyimmune checkpoint inhibitornivolumabpembrolizumab

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.8K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.1K

Related Experiment Videos

Last Updated: Sep 3, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.8K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.1K

Area of Science:

  • Oncology
  • Immunology
  • Clinical Research

Background:

  • Immune checkpoint inhibitors (ICIs) have revolutionized advanced melanoma treatment.
  • Real-world evidence is crucial as clinical trials may not represent diverse patient populations.
  • Immune-related adverse events (irAEs) are common with ICIs, and their predictive potential is under investigation.

Purpose of the Study:

  • To retrospectively analyze treatment data of advanced melanoma patients receiving single anti-PD-1 agents.
  • To identify potential predictive markers for treatment response and survival.
  • To evaluate the correlation between irAEs and clinical outcomes.

Main Methods:

  • Retrospective analysis of patient data over a 77-month period.
  • Patients treated with single anti-PD-1 agents (pembrolizumab or nivolumab).
  • Analysis of treatment efficacy, overall survival (OS), progression-free survival (PFS), and occurrence/grade of irAEs.

Main Results:

  • The occurrence of more than one irAE was correlated with response to PD-1 ICI therapy.
  • Patients experiencing multiple irAEs demonstrated improved OS and PFS.
  • The grade of irAE toxicity appeared to influence survival rates.

Conclusions:

  • Immune-related adverse events may serve as predictive markers for anti-PD-1 therapy in advanced melanoma.
  • The presence and severity of irAEs are associated with enhanced survival outcomes.
  • Further research into irAEs could refine patient selection and treatment strategies.